Global Innovative Drug R&D newsletter: Eli Lilly, MSD,Tessa Therapeutics,Innate Pharma,GSK

1 First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention Eli Lilly and Company...

Jul 11, 20235 min

Innovative Drug newsletter: bluebird bio Announces FDA Priority Review of the BLA for lovo-cel

R&D 1 Boston Pharmaceuticals Announces Positive Phase 2a Results from Monthly and Bi-weekly Dosing with Investigational BOS-580 NASH...

Jun 30, 20233 min

1. Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval Pfizer announced that the U.S. FDA has approved TALZENNA...